Thermo Fisher Scientific (TMO) Total Non-Current Liabilities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Total Non-Current Liabilities for 18 consecutive years, with $56.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 20.36% year-over-year to $56.0 billion; the trailing twelve-month figure through Jun 2026 stood at $56.0 billion (up 20.36% YoY), and the FY2025 full-year result was $52.7 billion, up 20.27% from the prior year.
• Total Non-Current Liabilities declined to $56.0 billion in Q2 2026 per TMO's latest filing, from $56.9 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $56.9 billion in Q1 2026 and bottomed at $42.5 billion in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $47.8 billion across 5 years, with a median of $47.1 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 71.08% in 2022, then decreased 7.56% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $48.9 billion in 2022, then fell by 3.12% to $47.4 billion in 2023, then fell by 7.56% to $43.8 billion in 2024, then gained by 20.27% to $52.7 billion in 2025, then climbed by 6.26% to $56.0 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $56.0 billion, $56.9 billion, and $52.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.